Cipla’s US subsidiary Invagen Pharmaceuticals will market Qilu Pharmaceutical’s QL2107, a biosimilar to Merck’s cancer drug Keytruda, in the United States
Source link
Cipla partners with Qilu to license, supply Keytruda biosimilar in US
Cipla’s US subsidiary Invagen Pharmaceuticals will market Qilu Pharmaceutical’s QL2107, a biosimilar to Merck’s cancer drug Keytruda, in the United States
Source link